Trading Signals: VXRT Stock Price Prediction and Forecast (Fri. Nov. 9, 2012 - Fri. May. 13, 2022)(Vaxart, Inc.)
| VXRT latest price $23.7600 (-1.37%) ($23.7600 - $24.3100) on Wed. Sep. 2, 2015. | |
| | Trend Analysis and Forecast | | | | Average Daily Percentage Swing | 2.37% (three month average) | | RSI | 30 | | Latest Price | $23.7600(-1.37%) | | Stocks Behave Similarly | Similar Stock List | | Daily Trend | VXRT advances 0.9% a day on average for past five trading days. | | Weekly Trend | VXRT declines -4% a week on average for past two weeks. | | Market Behavior | Broad based rally for large cap. Value stock rally for small cap. | | Correlated ETFs | Broad market will support VXRT advance at 0% a week (0% probability)
XBI(7%) ARKG(5%) XRT(5%) IBB(4%) XHB(4%) | | Factors Impacting VXRT price | VXRT will decline at least -1.185% in a week (0% probabilities).
SKYY(-7%) GLD(-5%) SLV(-4%) ICLN(-4%) GDX(-4%) | | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | | | | Relative Volatility | (options are extremely cheap) | | | | | Market Trend Strength | -1.185% (StdDev 2.37%) | | Hourly BBV | 0 () | | Intraday Trend | -2.3% | | | | | |
|
| Resistance Level | $24.69 | | 5 Day Moving Average | $23.45(1.32%) | | 10 Day Moving Average | $23.41(1.5%) | | 20 Day Moving Average | $24.69(-3.77%) | | To recent high | -13.3% | | To recent low | 8.5% | | Market Cap | $2.284b | | | | | | |
Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines. Its products include Influenza, Norovirus and Respiratory Syncytial Virus. The company was founded in 2004 and is headquartered in South San Francisco, CA.The big news for Vaxart, though, came just a couple of weeks ago. The U.S. government's Operation Warp Speed selected the company's COVID-19 vaccine candidate for funding and inclusion in a non-human primate challenge study. Vaxart's vaccine candidate was the only oral COVID-19 vaccine included. Vaxart expects to initiate its own phase 1 study of its COVID-19 vaccine in the second half of 2020. The study could begin as early as this summer. |